John Barbieri, M.D., MBA, associate professor at Harvard Medical School, discussed various topics based on his presentations at this year’s American Academy of Dermatology meeting about acne and rosacea with Managed Healthcare Executive.
Barbieri shared that in one session, his co-presenters highlighted energy-based therapies, including 1726-nanometer lasers for acne treatment, as well as advancements in acne management for skin of color, focusing on hyperpigmentation and new trials.
Another co-presenter discussed hormonal therapies for acne and rosacea, referencing the recent UK Soccer study on Spironolactone.
Barbieri shared insights on mood changes with Accutane, emphasizing a recent meta-analysis indicating a reduced suicide risk with isotretinoin compared to other acne therapies.
Regarding suicide and depression screening, he suggested using tools like the PHQ-2 or engaging in discussions with patients, stressing the importance of patient-reported outcomes like PHQ-2 and PROMIS measures in clinical practice.
Opzelura May Reduce Need for Other Treatments in Atopic Dermatitis | AAD 2025
March 11th 2025Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics during the 12 months after treatment with the topical nonsteroidal, according to study findings presented at the 2025 American Academy of Dermatology annual meeting.
Read More
Makeup and Skin Care Products Contain 'Forever Chemicals' | AAD 2025
March 10th 2025More than 200 products from 28 makeup, sunscreen, and shaving cream brands contained Teflon and other forever chemicals, according to a new study presented at the American Academy of Dermatology annual meeting.
Read More
Study Finds Opzelura Used As-Needed Improves Quality of Life | AAD 2025
March 10th 2025The reduction in itch was the greatest contributor to quality-of-life improvement for adolescents and adults with atopic dermatitis, according to a new study presented at the American Academy of Dermatology annual meeting.
Read More